Best Nanotechnology Stocks To Research – March 31st

OSI Systems, NVE, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks refer to shares in companies that develop and commercialize technologies at the nanoscale, often involving the manipulation of matter at the atomic or molecular level. These companies typically operate in fields such as electronics, healthcare, and advanced materials, offering potential growth from innovative breakthroughs while also carrying risks related to emerging technologies and market volatility. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

OSIS stock traded down $1.13 during trading hours on Monday, hitting $192.19. 83,176 shares of the stock were exchanged, compared to its average volume of 175,093. OSI Systems has a 12 month low of $126.57 and a 12 month high of $220.00. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $3.23 billion, a P/E ratio of 24.73, a P/E/G ratio of 1.81 and a beta of 1.20. The company has a 50-day simple moving average of $196.64 and a two-hundred day simple moving average of $171.33.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NVEC stock traded down $0.31 on Monday, hitting $64.68. The company’s stock had a trading volume of 17,082 shares, compared to its average volume of 21,100. NVE has a fifty-two week low of $62.78 and a fifty-two week high of $89.98. The company has a market capitalization of $312.86 million, a PE ratio of 20.86 and a beta of 1.08. The stock’s 50 day moving average is $70.06 and its 200-day moving average is $75.81.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

NASDAQ BDRX traded up $0.07 during trading on Monday, reaching $1.30. The company’s stock had a trading volume of 111,617 shares, compared to its average volume of 499,315. The company has a 50 day moving average of $3.39. Biodexa Pharmaceuticals has a 12 month low of $1.15 and a 12 month high of $74.00.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of VRPX stock traded down $0.15 during trading on Monday, hitting $1.19. The company had a trading volume of 116,977 shares, compared to its average volume of 179,868. Virpax Pharmaceuticals has a one year low of $1.17 and a one year high of $106.75. The stock’s 50-day moving average price is $5.65 and its 200 day moving average price is $10.64.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded down $0.18 during midday trading on Monday, reaching $3.05. The company had a trading volume of 28,279 shares, compared to its average volume of 78,071. Clene has a 1-year low of $3.01 and a 1-year high of $9.20. The stock has a 50 day moving average price of $4.43 and a 200-day moving average price of $4.84. The company has a market capitalization of $26.15 million, a price-to-earnings ratio of -0.57 and a beta of 0.27.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNNW stock remained flat at $0.03 during mid-day trading on Monday. 1 shares of the company’s stock traded hands, compared to its average volume of 14,500. The stock’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.04. Clene has a 52-week low of $0.02 and a 52-week high of $0.08.